Login to Your Account

Insmed Prices $26M Offering Focusing on CF lung infections

By Peter Winter
BioWorld Insight Editor

Monday, October 1, 2012
Monmouth Junction, N.J.-based Insmed Inc. has priced a $26 million direct public offering of approximately 6.3 million shares of its common stock at a price of $4.07 per share to certain affiliates of Ayer Capital, RA Capital and Quaker Partners.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription